G Youcef1,2,3,4, A Olivier1,2,3,5, N Nicot4, A Muller4, C Deng2,3,6, C Labat1,2,3, R Fay5,7, R-M Rodriguez-Guéant2,3,5,8, C Leroy1,7, F Jaisser5,7, F Zannad1,2,3,5,7, P Lacolley1,2,3,5, L Vallar4, A Pizard1,2,3,5,7. 1. UMRS U1116 Inserm, Nancy, France. 2. Fédération de Recherche 3209, Nancy, France. 3. Université de Lorraine, Nancy, France. 4. Genomics Research Unit, Luxembourg Institute of Health, Luxembourg. 5. CHU Nancy, Nancy, France. 6. UMR 7365 CNRS, Nancy, France. 7. CIC 1433 Inserm, Pierre Drouin, Nancy, France. 8. U954 Inserm, Nancy, France.
Abstract
BACKGROUND AND PURPOSE: Mineralocorticoid receptor (MR) activation contributes to heart failure (HF) progression. Its overactivity in obesity is thought to accelerate cardiac remodelling and HF development. Given that MR antagonists (MRA) are beneficial in chronic HF patients, we hypothesized that early MRA treatment may target obesity-related disorders and consequently delay the development of HF. EXPERIMENTAL APPROACH: Twenty spontaneously hypertensive HF dyslipidaemic obese SHHF(cp/cp) rats and 18 non-dyslipidaemic lean SHHF(+/+) controls underwent regular monitoring for their metabolic and cardiovascular phenotypes with or without MRA treatment [eplerenone (eple), 100 mg∙kg(-1) ∙day(-1) ] from 1.5 to 12.5 months of age. KEY RESULTS: Eleven months of eple treatment in obese rats (SHHF(cp/cp) eple) reduced the obesity-related metabolic disorders observed in untreated SHHF(cp/cp) rats by reducing weight gain, triglycerides and total cholesterol levels and by preserving adiponectinaemia. The MRA treatment predominantly preserved diastolic and systolic functions in obese rats by alleviating the eccentric cardiac hypertrophy observed in untreated SHHF(cp/cp) animals and preserving ejection fraction (70 ± 1 vs. 59 ± 1%). The MRA also improved survival independently of these pressure effects. CONCLUSION AND IMPLICATIONS: Early chronic eple treatment resulted in a delay in cardiac remodelling and HF onset in both SHHF(+/+) and SHHF(cp/cp) rats, whereas SHHF(cp/cp) rats further benefited from the MRA treatment through a reduction in their obesity and dyslipidaemia. These findings suggest that preventive MRA therapy may provide greater benefits in obese patients with additional risk factors of developing cardiovascular complications.
BACKGROUND AND PURPOSE:Mineralocorticoid receptor (MR) activation contributes to heart failure (HF) progression. Its overactivity in obesity is thought to accelerate cardiac remodelling and HF development. Given that MR antagonists (MRA) are beneficial in chronic HFpatients, we hypothesized that early MRA treatment may target obesity-related disorders and consequently delay the development of HF. EXPERIMENTAL APPROACH: Twenty spontaneously hypertensive HF dyslipidaemic obese SHHF(cp/cp) rats and 18 non-dyslipidaemic lean SHHF(+/+) controls underwent regular monitoring for their metabolic and cardiovascular phenotypes with or without MRA treatment [eplerenone (eple), 100 mg∙kg(-1) ∙day(-1) ] from 1.5 to 12.5 months of age. KEY RESULTS: Eleven months of eple treatment in obeserats (SHHF(cp/cp) eple) reduced the obesity-related metabolic disorders observed in untreated SHHF(cp/cp) rats by reducing weight gain, triglycerides and total cholesterol levels and by preserving adiponectinaemia. The MRA treatment predominantly preserved diastolic and systolic functions in obeserats by alleviating the eccentric cardiac hypertrophy observed in untreated SHHF(cp/cp) animals and preserving ejection fraction (70 ± 1 vs. 59 ± 1%). The MRA also improved survival independently of these pressure effects. CONCLUSION AND IMPLICATIONS: Early chronic eple treatment resulted in a delay in cardiac remodelling and HF onset in both SHHF(+/+) and SHHF(cp/cp) rats, whereas SHHF(cp/cp) rats further benefited from the MRA treatment through a reduction in their obesity and dyslipidaemia. These findings suggest that preventive MRA therapy may provide greater benefits in obesepatients with additional risk factors of developing cardiovascular complications.
Authors: Margarita Pizarro; Nancy Solís; Pablo Quintero; Francisco Barrera; Daniel Cabrera; Pamela Rojas-de Santiago; Juan P Arab; Oslando Padilla; Juan C Roa; Han Moshage; Alexander Wree; Eugenia Inzaugarat; Ariel E Feldstein; Carlos E Fardella; Rene Baudrand; Arnoldo Riquelme; Marco Arrese Journal: Liver Int Date: 2015-02-23 Impact factor: 5.828
Authors: Wojciech Kosmala; Monika Przewlocka-Kosmala; Hanna Szczepanik-Osadnik; Andrzej Mysiak; Thomas H Marwick Journal: Heart Date: 2013-01-23 Impact factor: 5.994
Authors: G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard Journal: Br J Pharmacol Date: 2016-04-26 Impact factor: 8.739
Authors: Daniel Ferguson; Irina Hutson; Eric Tycksen; Terri A Pietka; Kevin Bauerle; Charles A Harris Journal: Endocrinology Date: 2020-02-01 Impact factor: 4.736
Authors: G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard Journal: Br J Pharmacol Date: 2016-04-26 Impact factor: 8.739
Authors: Raffaele Altara; Mauro Giordano; Einar S Nordén; Alessandro Cataliotti; Mazen Kurdi; Saeed N Bajestani; George W Booz Journal: Front Endocrinol (Lausanne) Date: 2017-07-17 Impact factor: 5.555